Clinical trials: Systemic Sclerosis Pulmonary
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Sclerosis
Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
Although the aetiology of SSc-PAH remains elusive, vascular dysfunction seems to be the initial event and statins through their vasculoprotective effect might be of value in the treatment armamentarium of PAH related to SSc.
- Trial name
- NCT00984932
- Testing
- Rosuvastatin
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Alexandria
Systemic Lupus, Rheumatoid Arthritis
Yellow Fever Vaccine in Patients With Rheumatic Diseases
According to World Health Organization (WHO), since December 2016, Brazil is showing a significant increase in cases of yellow fever in humans.
- Conditions
- Systemic Lupus, Rheumatoid Arthritis, Spondyloarthritis, Inflammatory Myopathy
- Trial name
- NCT03430388
- Testing
- Yellow Fever vaccine (17D)
- Where
- Brazil
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Systemic Sclerosis, Diffuse Sclerosis Systemic
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment…
- Conditions
- Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
- Trial name
- SSc (NCT03630211)
- Testing
- Cyclophosphamide, Mesna, Rituximab
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Paul Szabolcs
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Hormonal, Metabolic, and Signaling Interactions in PAH
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
- Trial name
- NCT01884051
- Where
- United States
- Volunteers
- 1,899 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Refractory Lupus Nephritis, Systemic Sclerosis
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), primary Sjogren syndrome combined with pulmonary artery hypertension…
- Conditions
- Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, Other Autoimmune Diseases (AID)
- Trial name
- NCT06947460
- Testing
- CD19-BCMA CAR-T cells infusion
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing GoBroad Hospital
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Systemic Sclerosis, Interstitial Lung Diseases
Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis
Systemic sclerosis (SSc) is an orphan, multiorgan disease affecting the connective tissue of the skin and all internal organs. Interstitial lung disease is a frequent morbidity and mortality-driving manifestation in systemic…
- Trial name
- NCT01858259
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 1,372 people
- Sponsor
- Gabriela Riemekasten
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Lung Diseases, Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases
To conduct cross-sectional and longitudinal studies of patients with idiopathic pulmonary fibrosis (IPF) and patients with progressive systemic sclerosis (PSS), with and without associated lung disease.
- Conditions
- Lung Diseases, Pulmonary Fibrosis, Lung Diseases, Interstitial, Scleroderma, Systemic
- Trial name
- NCT00005317
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis
This protocol is of a systematic review for risk factors of pulmonary arterial hypertension in systemic sclerosis.
- Trial name
- NCT03889509
- Where
- Canada
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Diffusion Limitation of Pulmonary Gas Exchange in Systemic Sclerosis
Mechanisms of Pulmonary Diffusion Limitation in Systemic Sclerosis
This study was designed to test the hypothesis that, irrespective of the degree of interstiaI lung disease and/or pulmonary arterial hypertension, the combined measurement of lung diffusing capacity for nitric oxide and carbon…
- Trial name
- DL-SSc (NCT03601520)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Refractory Lupus Nephritis, Systemic Sclerosis
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), and primary Sjogren syndrome combined with pulmonary artery hypertension…
- Conditions
- Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension
- Trial name
- NCT06947473
- Testing
- umbilical cord blood CD19-BCMA CAR-T cells infusion
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing GoBroad Hospital
Pulmonary Hypertension
Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a condition characterized by an increased pulmonary vascular resistance that can lead to right heart failure and death.
- Trial name
- NCT01729611
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- The Cleveland Clinic
Pulmonary Hypertension
Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the safety and efficacy of Thelin™ (sitaxsentan sodium) compared to placebo (sugar pill) in the treatment of patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00080457
- Testing
- sitaxsentan sodium
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Encysive Pharmaceuticals
Interstitial Lung Diseases
Monitoring and Evaluation Study of Project ECHO for ILD
The study will utilize pre-post survey measures to evaluate Project ECHO for ILD with respect to an initial set of practice and clinical outcomes and relies on questionnaire data obtained from providers participating in Project…
- Trial name
- NCT05455437
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Pulmonary Care and Research Collaborative Limited
Systemic Sclerosis, Pulmonary Hypertension
Development and Prevention of Pulmonary Hypertension in Systemic Sclerosis
Systemic sclerosis (SSc) is an orphan, multiorgan disease affecting the connective tissue of the skin and several internal organs.
- Trial name
- NCT01840748
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 960 people
- Sponsor
- University of Paris 5 - Rene Descartes